A patent reform bill being argued in Congress has drawn a significant amount of protest from the biotech industry. But with a wide array of groups looking to influence the legislation, including the White House, the bill appears to have stalled in a Senate committee. High-tech companies, meanwhile, have been actively pushing for its passage. Report [1]
Links:
[1] http://www.sdbj.com/industry_article.asp?aID=740571.3182516.1603667.1315912.2261792.776&aID2=123350